Ritu Baral
Stock Analyst at TD Cowen
(0.98)
# 3,712
Out of 4,884 analysts
36
Total ratings
40%
Success rate
-13.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $44 | $24.12 | +82.42% | 1 | Feb 5, 2025 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $9 | $9.20 | -2.17% | 6 | Nov 21, 2024 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $2.91 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.05 | - | 2 | Nov 18, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $29.17 | +167.40% | 1 | Oct 21, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $331.91 | +11.78% | 4 | Oct 21, 2024 | |
| INSM Insmed | Maintains: Buy | $75 → $98 | $97.80 | +0.20% | 3 | Aug 9, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $298.87 | +30.49% | 1 | Mar 15, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $8.25 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $18.24 | +859.43% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $21 | $20.95 | +0.24% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.33 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.92 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.77 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $24.00 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.32 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.26 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.59 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $795.48 | - | 2 | Jan 12, 2018 |
Palvella Therapeutics
Feb 5, 2025
Initiates: Buy
Price Target: $44
Current: $24.12
Upside: +82.42%
Sage Therapeutics
Nov 21, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $9.20
Upside: -2.17%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.91
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.05
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $29.17
Upside: +167.40%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $331.91
Upside: +11.78%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75 → $98
Current: $97.80
Upside: +0.20%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $298.87
Upside: +30.49%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $8.25
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $18.24
Upside: +859.43%
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $20.95
Upside: +0.24%
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.33
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.92
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.77
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $24.00
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.32
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.26
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.59
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $795.48
Upside: -